2-(1H-咪唑-4-基)吡啶 | 16576-78-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(1H-咪唑-4-基)吡啶
• 英文名称: 4(5)-(2-pyridinyl)imidazole
• 英文别名: 2-(3H-imidazol-4-yl)pyridine；2-(1H-imidazol-5-yl)pyridine
• CAS: 16576-78-6
• 化学式: C₈H₇N₃
• mdl: MFCD08668576
• 分子量: 145.164
• InChiKey: AHHQCRZKQHDXIY-UHFFFAOYSA-N

物化性质

• 熔点：
  40-41 °C
• 沸点：
  406.8±20.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(1H-咪唑-4-基)吡啶 在 manganese(IV) oxide 、 sodium hydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正庚烷 、 二氯甲烷 、 乙基苯 为溶剂， 反应 1.5h， 生成 [1-(4-chloro-benzyl)-1H-indol-3-yl]-[4-pyridin-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-methanone
  参考文献：
  名称：

  Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines

  摘要：

  We report herein the SAR studies of a series of indole-imidazole compounds. that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance (MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types, including hematologic and solid tumor cell lines of various origins (e.g., leukemia, breast, colon, and uterine). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.020
• 作为产物：
  描述：

  2-[4-(Toluene-4-sulfonyl)-4,5-dihydro-oxazol-5-yl]-pyridine 在 氨 作用下， 以 甲醇 为溶剂， 反应 20.0h， 以90%的产率得到2-(1H-咪唑-4-基)吡啶
  参考文献：
  名称：

  A convenient set of bidentate pyridine ligands for combinatorial synthesis

  摘要：

  Synthesis is reported of five pyridine-containing bidentate ligands bearing nucleophilic groups at different positions. Their efficient solid-phase alkylation was demonstrated in the synthesis of a small library. These ligands are attractive building blocks for the construction of libraries of metal-binding compounds for various purposes. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00885-0

文献信息

• PROCESS FOR PREPARING A PROPIOLIC ACID OR A DERIVATIVE THEREOF
  申请人：Goossen Lukas J

  公开号：US20140012000A1

  公开（公告）日：2014-01-09

  The invention relates to a process for preparing a propiolic acid or a derivative thereof by reacting a terminal alkyne with carbon dioxide, which comprises performing the reaction in the presence of a base and a copper complex, especially a copper (I) complex having at least one ligand, at least one of the ligands of the copper complex being selected from monodentate ligands which have an aminic or iminic nitrogen atom capable of coordination with copper, and polydentate ligands having at least two atoms or atom groups which are capable of simultaneous coordination with copper and are selected from nitrogen, oxygen, sulfur, phosphorus and carbene carbon.

  该发明涉及一种通过将末端炔烃与二氧化碳反应制备丙炔酸或其衍生物的方法，其中在碱和铜络合物的存在下进行反应，特别是在至少具有一个配体的铜（I）络合物的存在下进行反应，铜络合物的配体中至少有一个被选择自具有能够与铜配位的氨基或亚胺基氮原子的一价配体，以及具有至少两个能够与铜同时配位的原子或原子团的多齿配体，这些原子或原子团被选择自氮、氧、硫、磷和卡宾碳。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20150065522A1

  公开（公告）日：2015-03-05

  The present invention relates to compounds formula (I): and to salts thereof, wherein R 1 -R 4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及化合物的化学式（I）及其盐，其中R1-R4和A具有规范中定义的任何值，以及这些化合物的组合物和用途。这些化合物可用作组蛋白去甲基化酶的抑制剂，如KDM5。还包括包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• DPP IV inhibitors
  申请人：——

  公开号：US20030130281A1

  公开（公告）日：2003-07-10

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明涉及以下式（I）的化合物： 其中R1、R2和X如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• Tri-substituted heteroaryls and methods of making and using the same
  申请人：Lee Wen-Cherng

  公开号：US20060063809A1

  公开（公告）日：2006-03-23

  Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of the general formula (I).

  公式(I)的化合物对Alk 5和/或Alk 4具有意外的亲和力，可以用作拮抗剂，用于预防和/或治疗包括纤维化疾病在内的多种疾病。在一个实施例中，发明特点是一种通用公式(I)的化合物。